- Trials with a EudraCT protocol (1,346)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (164)
1,346 result(s) found for: Lymphoma.
Displaying page 1 of 68.
EudraCT Number: 2006-002141-37 | Sponsor Protocol Number: HOVON 80 NHL | Start Date*: 2006-09-28 | |||||||||||
Sponsor Name:HOVON foundation | |||||||||||||
Full Title: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with intrathecal rituximab, followed by autologous stem cell transplantation in patients with a recurrent aggressive B-ce... | |||||||||||||
Medical condition: relapsed B cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001888-40 | Sponsor Protocol Number: DEP NHL-P 001.A | Start Date*: 2006-07-24 | |||||||||||
Sponsor Name:Mundipharma Research Ltd. | |||||||||||||
Full Title: A phase II prospective non-comparative multicenter clinical trial to determine the efficacy and safety of intrathecal liposomal cytarabine (DepoCyte®) in preventing CNS-relapse in patients with agg... | |||||||||||||
Medical condition: Prophylaxis of CNS relapse in adult patients with aggressive Non-Hodgkin-Lymphomas at risk for CNS metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004908-37 | Sponsor Protocol Number: IRIS | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Phase II study on activity and tolerability of intralesional rituximab in relapsed or refractory patients affected by indolentCD-20 positive lymphoma of conjuntiva; evaluation of activity of adding... | |||||||||||||
Medical condition: indolent CD-20 positive lymphoma of conjunctiva | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000434-47 | Sponsor Protocol Number: IM-T-hA20-08 | Start Date*: 2008-07-22 | ||||||||||||||||
Sponsor Name:Immunomedics, Inc. | ||||||||||||||||||
Full Title: A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia | ||||||||||||||||||
Medical condition: Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002865-39 | Sponsor Protocol Number: TCD12333 | Start Date*: 2012-10-03 | |||||||||||
Sponsor Name:sanofi-aventis recherche et développement | |||||||||||||
Full Title: An open label, multicenter phase II study of intravenous SAR3419, an anti-CD19 antibody-maytansine conjugate, in combination with rituximab in patients with relapsed or refractory Diffuse Large B C... | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001666-32 | Sponsor Protocol Number: APM4083g | Start Date*: 2007-12-05 | |||||||||||
Sponsor Name:Genentech Inc | |||||||||||||
Full Title: A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULA... | |||||||||||||
Medical condition: Follicular, CD20-Positive B-Cell Non-Hodgkin's Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) BE (Completed) GB (Prematurely Ended) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003824-12 | Sponsor Protocol Number: ProRom | Start Date*: 2011-10-21 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Pilot phase II trial on safety and activity of secondary prophylaxis with Romiplostim in patients with non-Hodgkin lymphoma and chemotherapy-induced throm-bocytopenia | |||||||||||||
Medical condition: chemotherapy-induced thrombocytopenia in patients affected by non-Hodgkin lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003511-20 | Sponsor Protocol Number: 201700599 | Start Date*: 2019-01-30 | |||||||||||||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||||||||||||
Full Title: Molecular imaging of zirconium-89-labeled atezolizumab in high-risk diffuse large B-cell lymphoma prior to atezolizumab treatment | |||||||||||||||||||||||
Medical condition: Diffuse large B-cell Lymphoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015504-25 | Sponsor Protocol Number: GAO4753g | Start Date*: 2010-06-04 | |||||||||||
Sponsor Name:GENENTECH, Inc | |||||||||||||
Full Title: An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, ... | |||||||||||||
Medical condition: CD20+, indolent NHL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) AT (Completed) DE (Completed) FR (Completed) IT (Completed) GB (Completed) ES (Completed) SE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022812-37 | Sponsor Protocol Number: ORH/PID/6265 | Start Date*: 2011-06-07 | |||||||||||
Sponsor Name:Oxford University Hospitals NHS Trust | |||||||||||||
Full Title: A phase 2 trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma | |||||||||||||
Medical condition: Diffuse Large B-cell Lymphoma (DLBCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003645-42 | Sponsor Protocol Number: CA209-140 | Start Date*: 2014-02-03 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A single arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) Revised protocol 03a, including amendment 04 and 05 | |||||||||||||
Medical condition: Lymphoma. Non-Hodgkin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) ES (Prematurely Ended) IT (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002406-31 | Sponsor Protocol Number: IPI-145-08 | Start Date*: 2014-09-16 | |||||||||||
Sponsor Name:Infinity Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of IPI-145 in Combination with Rituximab vs Rituximab in Subjects with Previously-Treated Follicular Lymphoma | |||||||||||||
Medical condition: Follicular Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Prematurely Ended) HU (Completed) ES (Completed) BE (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001570-17 | Sponsor Protocol Number: LYMRIT-37-06 | Start Date*: 2015-09-14 | ||||||||||||||||
Sponsor Name:Nordic Nanovector ASA | ||||||||||||||||||
Full Title: A Phase 2 study of the antibody-radionuclide-conjugate 177Lu-DOTA-HH1 (Betalutin™) in patients with CD37-positive relapsed follicular lymphoma | ||||||||||||||||||
Medical condition: Relapsed CD37+ non-Hodgkin B-cell follicular lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) AT (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003796-20 | Sponsor Protocol Number: HOVON 77 | Start Date*: 2007-01-03 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission f... | |||||||||||||
Medical condition: patients with diffuse Large B-Cell lymphoma, CD20-positive | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003657-26 | Sponsor Protocol Number: ARD10248 | Start Date*: 2012-01-16 | |||||||||||
Sponsor Name:sanofi aventis recherche et développement | |||||||||||||
Full Title: An open label non-randomized phase 2 study evaluating SAR3419, an anti-CD19 antibody – maytansine conjugate, administered as single agent by intravenous infusion to patients with relapsed or refrac... | |||||||||||||
Medical condition: Diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) BE (Completed) ES (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002524-42 | Sponsor Protocol Number: FM-DLBCL06-01 | Start Date*: 2006-09-20 | |||||||||||
Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI | |||||||||||||
Full Title: Use of mieloablative doses of zevalin in aggressive lymphomas of the elderly. Prospective randomized study Z-HDS1,2 vs R-CHOP | |||||||||||||
Medical condition: Aggressive malignant lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001519-52 | Sponsor Protocol Number: LNH 03-6B | Start Date*: 2007-12-14 | |||||||||||
Sponsor Name:Groupe d'Etudes des Lymphomes de l'Adult | |||||||||||||
Full Title: Randomized study of intensified CHOP plus Rituximab (R-CHOP given every 14 days: R-CHOP 14) versus CHOP plus Rituximab given every 21 days (R-CHOP 21) and randomized study of frontline-prophylatic ... | |||||||||||||
Medical condition: Study of frontline-prophylatic darbepoetin alpha treatment versus usual symptomatic treatment of anemia in non previously treated patients aged 60 to 80 years, with CD20+ diffuse large B-cell lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001055-38 | Sponsor Protocol Number: IELSG20 | Start Date*: 2003-11-28 | |||||||||||
Sponsor Name:INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP IELSG | |||||||||||||
Full Title: RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE, ALONE OR ASSOCIATED WITH HIGHDOSE CYTARABINE, FOLLOWED BY RESPONSE- AND AGE-TAILORED RADIOTHERAPY FOR IMMUNOCOMPETENT ... | |||||||||||||
Medical condition: primary chemotherapy of primary central nervous system lymphoma with high dose cytarabine plus methotrexate | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004851-39 | Sponsor Protocol Number: 109/2006/U/Sper | Start Date*: 2006-10-03 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENT TREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN) IN ELDERLY ( 60 YEARS) PATIENTS WITH DI... | |||||||||||||
Medical condition: DIFFUSE LARGE BCELL LYMPHOMA | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012143-42 | Sponsor Protocol Number: HEART01 | Start Date*: 2009-10-08 | |||||||||||
Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS | |||||||||||||
Full Title: Multicenter study of phase II with Rituximab, cyclophosphamide, doxorubicin liposomal (Myocet), vincristine, Prednisone, (R-COMP) in diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopath... | |||||||||||||
Medical condition: Diffuse Non-Hodgkin`s lymphoma, large B cells of the cardiopathic patient | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
